Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$22.67M$22.67M−38.2% vs Q2 2019 Net Income-$55.19M-$55.19MN/M vs Q2 2019 EPS Diluted-$0.61-$0.61N/M vs Q2 2019 Gross Profit$13,663,000−40.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$57,277,000N/M Free Cash Flowderived-$58,026,000N/M Margins · derivedGross margin60.3%−2.7 pt vs Q2 2019
Operating margin-245.9%−104.7 pt vs Q2 2019
Net margin-243.5%−106.5 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 5, 2020 · 36 d after period end